...
首页> 外文期刊>The American journal of geriatric pharmacotherapy >Separate episodes of delirium associated with levetiracetam and amiodarone treatment in an elderly woman.
【24h】

Separate episodes of delirium associated with levetiracetam and amiodarone treatment in an elderly woman.

机译:一名老年妇女单独出现le妄与左乙拉西坦和胺碘酮治疗相关。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Delirium related to levetiracetam has not been previously described in the literature and is infrequently associated with amiodarone. OBJECTIVE: The aim of this report was to discuss the possibility that administration of levetiracetam and amiodarone may precipitate delirium in some elderly patients. CASE SUMMARY: An 80-year-old white woman with levothyroxine-treated hypothyroidism developed acute confusion and paranoia 5 days after substituting levetiracetam 1000 mg orally twice daily for phenytoin 100 mg orally twice daily to control new, generalized seizures. Before starting levetiracetam treatment, results of the patient's blood and urine tests, brain magnetic resonance imaging, and cerebrospinal fluid examination were within normal limits. Delirium from levetiracetam was suspected. Therefore, the dosage was titrated downward to allow discontinuation of the drug; levetiracetam was replaced with pregabalin 150 mg twice daily. Subsequent improvement in mental status occurred within 14 days after administration of the last dose of levetiracetam. Three months later, the patient developed symptomatic atrial fibrillation, which was treated with cardioversion, followed by oral amiodarone 400 mg twice daily for 10 days and then 200 mg once daily for 3 months. Within 1 to 2 weeks after starting amiodarone, she developed changes in cognition consistent with delirium. Computed tomography of the brain showed no acute changes, and blood test results were within normal limits with the exception of a serum free thyroxine level of 2.06 ng/dL and a suppressed but measurable serum thyroid-stimulating hormone level (0.13 microIU/mL). No improvement was noted after reduction of the dose of levothyroxine from 0.1 mg to 0.075 mg daily. Two weeks after amiodarone was discontinued, her mental status had returned to baseline levels. Based on a score of 6 (probable) for each medication using the Naranjo scale, the 2 episodes of delirium were probably related to levetiracetam and amiodarone. CONCLUSION: This case report describes separate episodes of delirium probably related to treatment with levetiracetam and amiodarone in an elderly patient.
机译:背景:与左乙拉西坦有关的Deli妄以前没有在文献中描述过,很少与胺碘酮有关。目的:本报告的目的是讨论左乙拉西坦和胺碘酮的使用可能在某些老年患者中引起del妄的可能性。病例摘要:一位接受左甲状腺素治疗的甲状腺功能减退症的80岁白人妇女在每天两次口服1000 mg左乙拉西坦代替口服苯妥英100 mg每天两次以控制新的全身性癫痫发作后5天出现急性意识混乱和妄想狂。在开始左乙拉西坦治疗之前,患者的血液和尿液检查,脑磁共振成像以及脑脊液检查结果均在正常范围内。怀疑左乙拉西坦有妄。因此,将剂量向下滴定以允许停药。左乙拉西坦每天两次用普瑞巴林150 mg代替。在最后一次服用左乙拉西坦后的14天内,精神状态得到了改善。三个月后,患者出现了症状性心房颤动,并接受了心脏复律治疗,随后口服胺碘酮400 mg,每天两次,持续10天,然后每天200 mg,一次,持续3个月。在开始使用胺碘酮后的1至2周内,她出现了与del妄一致的认知变化。脑部计算机断层扫描未显示任何急性变化,血液检测结果在正常范围内,但血清游离甲状腺素水平为2.06 ng / dL,血清促甲状腺激素水平被抑制但可测量(0.13 microIU / mL)。将左甲状腺素的剂量从每天0.1 mg减少到0.075 mg后,没有发现改善。停用胺碘酮两周后,她的精神状态恢复到基线水平。基于使用Naranjo量表的每种药物的得分为6(可能),,妄的2次发作可能与左乙拉西坦和胺碘酮有关。结论:该病例报告描述了separate妄的独立发作,可能与老年患者左乙拉西坦和胺碘酮治疗有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号